Patents for A61P 35 - Antineoplastic agents (221,099)
08/2008
08/28/2008WO2008084040A8 Use of mage a3-protein d fusion antigen in immunotherapy combined with surgery, chemotherapy or radiotherapy for the treatment of cancer
08/28/2008WO2008083239A3 Compositions and methods for stimulating an immune response
08/28/2008WO2008076779A3 2-(piperidin-4-yl0xy)pyrimidin-4-amine derivatives as deoxycytidine kinase inhibitors for the treatment of cancer
08/28/2008WO2008073785A3 Phosphoinositide 3-kinase inhibitor compounds and methods of use
08/28/2008WO2008070041A3 Inhibitors of akt activity
08/28/2008WO2008039489A3 5-substituted quinazolinone derivatives as antitumor agents
08/28/2008WO2008033891A3 Azonafide derived tumor and cancer targeting compounds
08/28/2008WO2008033851A3 Use of 2-6- (3-amino-piperidin-l-yl) -3-methyl-2, 4-dioxo-3, 4-dihydr0-2h-pyrimidin-1-ylmet hyl-4-fluoro-benzonitrile
08/28/2008WO2008019823A3 Use of certain chemical compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins
08/28/2008WO2007127506A8 Anti-ephrinb2 antibodies and methods using same
08/28/2008WO2007102769A3 Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them
08/28/2008WO2007098091A3 Treatment of hyperproliferative diseases with vinca alkaloid n-oxide and analogs
08/28/2008WO2007092720A8 Vitamin d analog: nel, methods and uses thereof
08/28/2008WO2007087488A9 Indole sulfonamide modulators of progesterone receptors
08/28/2008US20080207947 Injection; intratumor insertion
08/28/2008US20080207883 Platelet Derived Growth Factor (PDGF) Nucleic Acid Ligand Complexes
08/28/2008US20080207764 Novel Benzamidine Derivatives Having Anti-Inflammatory and Immunosuppressive Activity
08/28/2008US20080207751 Non-steroid antiinflammatory compound derivative of sulindac
08/28/2008US20080207746 Administering an ultrasonic contrast agent; imaging tissue; medical diagnosis; using halogenated xanthene compound
08/28/2008US20080207744 Anticancer agents
08/28/2008US20080207743 Anticancer agents
08/28/2008US20080207730 Methods of using (+)-2-[1-(3-Ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
08/28/2008US20080207729 Chemoosensitizer for dug resistance tumors
08/28/2008US20080207724 Use of Inhibitors of Histone Deacteylases in Combination With Compounds Acting as Nsaid for the Therapy of Human Diseases
08/28/2008US20080207716 Formulations and Dosing Regiment for Ppar-Alpha Modulators
08/28/2008US20080207714 Diagnosis And Treatment Of Breast Cancer
08/28/2008US20080207706 Thiadiazoline derivative
08/28/2008US20080207699 Pyrazole Derivatives
08/28/2008US20080207693 Mitotic Kinesin Inhibitors
08/28/2008US20080207683 Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s
08/28/2008US20080207682 Phenylurea Derivatives As Inhibitors Of Tyrosine Kinases For The Treatment Of Tumour Diseases
08/28/2008US20080207677 Napthyridine Compounds As Rock Inhibitors
08/28/2008US20080207673 Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins
08/28/2008US20080207658 Mixture of pyrimidylaminobenzamide and kinase inhibitor
08/28/2008US20080207657 Use Of Minoxidil Sulfate As An Anti-Tumor Drug
08/28/2008US20080207653 Antitumor agents
08/28/2008US20080207652 Novel inhibitors of folic acid-dependent enzymes
08/28/2008US20080207647 Pyrazole Derivatives Having Tyrosine Kinase Activity
08/28/2008US20080207644 Administering in mouth or mucous membrane; anticancer agents; administering phosphodiesterase inhibitor , map kinase inhibitor, proteasome inhibitor
08/28/2008US20080207642 Respiratory system disorders; asthma; chronic obstructive pulmonary diseases; autoimmune diseases; antiproliferative agents; anticancer agents
08/28/2008US20080207640 Administering drug; anticancer agents; antitumor agents
08/28/2008US20080207635 Tyrosine kinase moderators; anticancer agents; antidiabetic agents; restenosis; arteriosclerosis ; skin disorders;
08/28/2008US20080207634 Chemical Compounds
08/28/2008US20080207632 Protein kinase inhibitors
08/28/2008US20080207630 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators
08/28/2008US20080207617 Prevent autophosphorylation of tyrosine kinase; therapy for hematopoietic cancer; leukemia; myelodysplastic syndrome
08/28/2008US20080207616 Anticancer agents; for humans, animals
08/28/2008US20080207615 Using allelic variations in epidermal growth factor gene as evaluative tool in predicting positive response to anticancer agents, therapy; administering gefitinib
08/28/2008US20080207611 Anticancer agents; kinase inhibitors; viricides; antiinflammatory agents; immunotherapy; metabolism disorders
08/28/2008US20080207609 Anticancer agents; kinase inhibitor; immunotherapy; viricides; antiinflammatory agents
08/28/2008US20080207606 Immunology diseases; analgesics; antiarthritic agents; cardiovascular disorders; antiischemic agents; skin disorders;antiulcer agents; bone disorders; antihistamines
08/28/2008US20080207605 Administering combination of metalloproteinase and caspase inhibitors
08/28/2008US20080207603 Methods of Chemical Synthesis and Purification of Diaminophenothiazinium Compounds Including Methylthioninium Chloride (Mtc)
08/28/2008US20080207591 Organic Compounds
08/28/2008US20080207589 Cyclized derivatives as eg-5 inhibitors
08/28/2008US20080207588 Spiro-Heterocyclic Chromans, Thiochromans and Dihydroquinolines
08/28/2008US20080207578 Inducing a cytostatic effect on cancer cells by administering cucurbitacin B or cucurbitacin D; industrial scale; antitumor agents; breast, brain, colon, ovarian, lung, prostate, and kidney cancer; melanoma, leukemia, retinoblastoma
08/28/2008US20080207568 Class of Gamma Delta T Cells Activators and Use Thereof
08/28/2008US20080207566 Methods for the administration of amifostine and related compounds
08/28/2008US20080207564 Derivaitves of 4-Or 5-Aminosalicylic Acid
08/28/2008US20080207563 Synergistic sequential or simultaneous administration of erlotinib and a MEK inhibiting N-substituted-{2,5-dioxo-imidazolidin-1-yl}-3-phenyl-butyramide
08/28/2008US20080207557 A time-release formulation of a water-soluble derivative having the fatty acid moiety removed and an antiinflammatory agent; opoid resistant neuropathic pain, amputation pain or neuralgia;
08/28/2008US20080207554 Oligonucleotides with phosphotriester linkages; ribonuclease L activators; antineoplastic agents, namely against leukemias, viricides, parasiticides for Chagas' Disease; nucleotide chemical synthesis
08/28/2008US20080207550 Immunomodulatory polynucleotides and methods of using the same
08/28/2008US20080207545 Using antisense oligonucleotides, small interfering RNA, and ribozymes to inhibit expression of the human steroid 5 alpha-reductase gene and thereby inhibit formation of dihydrotestosterone: skin diseases, hair loss, hirsuitism, and benign prostatic hyperplasia
08/28/2008US20080207538 Enhanced Production of Functional Proteins From Defective Genes
08/28/2008US20080207532 Use of Nordihydroguaiaretic Acid Derivatives in the Treatment of Drug Resistant Cancer, Viral and Microbial Infection
08/28/2008US20080207525 Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; bioavailability; coupling; chemical intermediates
08/28/2008US20080207523 Compounds as aptamer-dimers and their uses in diagnosis and therapy
08/28/2008US20080207521 Polypeptide encoding amino acid sequence including MDGCEL (formylated Met-Asp-Gly-Cys-Glu-Leu) hexapeptide; antitumor and antimetastatic agents for treatment of breast, colon, thyroid, and nervous system cancer; mimic effects of Wnt-5a protein; increased adhesion impairs cancer cell migration
08/28/2008US20080207517 SELECTIVE INHIBITION OF NF-kappaB ACTIVIATION BY PEPTIDES DESIGNED TO DISRUPT NEMO OLIGOMERIZATION
08/28/2008US20080207516 Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
08/28/2008US20080207506 Nucleic acid sequence coding Mammastatin; protein useful in diagnosis, therapy fo breast cancer ; antigrowth agents
08/28/2008US20080207502 Anti-Angiogenic Peptides and Methods of Use Thereof
08/28/2008US20080207497 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
08/28/2008US20080207489 Use of CCN5 for treatment of smooth muscle proliferation disorders
08/28/2008US20080207484 Polypeptides; hybrid nucleic acids; anticancer agents; central nervous system disorders
08/28/2008US20080206835 Methods and Compositions Relating to Gene Silencing
08/28/2008US20080206753 determining the level of expression of at least one Notch receptor gene, Notch ligand gene or Notch signaling target gene; lower level of expression compared to the level of expression in the cell or cells in the absence of the compound indicates the potential usefulness of the compound in the treatment
08/28/2008US20080206379 Production and Use of an Antioxidant Extract from Crypthecodinium Sp.
08/28/2008US20080206375 Composition of Radix Codonopsis and Radix Astragali, a Method for Preparation Thereof and its Application
08/28/2008US20080206374 Purification, washing with deionized water, heating and extracting, condensing, depositing with ethanol; immunomodulators, antiischemic agents
08/28/2008US20080206318 Administering complex formed from a soluble tumor-associated antigen and an antibody or antigen binding fragment thereof that binds to a first epitope of the tumor-associated antigen, wherein the tumor-associated antigen is CA 125 for therapy of oncological disease
08/28/2008US20080206312 Therapeutic Morpholino-Substituted Compounds
08/28/2008US20080206286 Brain tumors; dendritic cells pulsed with antigens from isolated cancer stem cells provided a significant survival benefit
08/28/2008US20080206270 vaccines that rely on eliciting cellular immune responses, specifically induction of cytotoxic T lymphocytes (CTL), against cancer cells and virus-infected cells via administration of a vaccine comprising a fusion peptide or a modified peptide; derived from antigens PRAME, OFA/iLRP, STEAP and SURVIVIN
08/28/2008US20080206268 HA-1 epitopes and uses thereof
08/28/2008US20080206265 Using oligonucleotide immunostimulant mixture with drug; Modification of an immunostimulatory oligonucleotide to optimally present 5' ends dramatically enhances its anti-cancer activity
08/28/2008US20080206258 Novel Tetrahydropyridothiophenes
08/28/2008US20080206257 Reducing epithelial toxicity during cancer therapy by administering KGF with e.g. erlotinib, Iressa(TM), canertinib, or a monoclonal antibody against EGFR; side effect reduction of diarrhea, rash
08/28/2008US20080206256 Treatments for cancer
08/28/2008US20080206255 Antibody cancer immunotherapy
08/28/2008US20080206252 Novel Polypeptides, and Nucleic Acids Encoding the Same
08/28/2008US20080206249 comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides
08/28/2008US20080206245 Compositions and methods for the therapy and diagnosis of breast cancer
08/28/2008US20080206244 Compositions and methods for the therapy and diagnosis of breast cancer
08/28/2008US20080206238 Angiogenesis-Inhibiting Chimeric Protein and the Use
08/28/2008US20080206235 Vaccine mixture comprising B7-H4 antagonist for use in prevention and treatment of infection and/or cancer
08/28/2008US20080206234 Compositions and methods for the therapy and diagnosis of breast cancer
08/28/2008US20080206230 Peptides Derived from Human Bplp Protein, Polynucleotides Coding for Said Peptides and Antibodies Directed Against Said Peptides